Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Voluntary written informed consent of the subject obtained before any study-specific procedure.~2. Histologically or cytologically confirmed malignant solid tumor or lymphoma.~3. Subjects with malignancies that are not otherwise curable or for which no effective standard therapy exists.~4. Age ≥ 18 years.~5. Subject with measurable or non-measurable disease using the RECIST criteria~6. Recovery from any drug-related adverse event related to previous treatment, excluding alopecia and NCI-CTCAE grade \< 2 peripheral neuropathy.~7. Laboratory values within 7 days prior to first infusion:~   * Platelet count ≥ 100 x109/L, hemoglobin ≥ 9 g/dL and absolute neutrophil count (ANC) ≥ 1.5 x109/L.~  * Alkaline phosphatase ≤ 2.5 x the upper limit of normal (ULN) (≤ 5 x ULN in case of extensive bone metastases)~  * Aspartate aminotransferase (AST): ≤ 2.5 x ULN~  * Alanine aminotransferase (ALT): ≤ 2.5 x ULN~  * Total bilirubin: ≤ 1.5 ULN, unless due to Gilbert's syndrome.~  * Creatinine: ≤ ULN, or calculated creatinine clearance: ≥ 60 mL/min (calculated from the Cockcroft-Gault formula; see Appendix III).~  * Albumin: ≥ 2.5 g/dL.~  * Partial thromboplastin within normal limits for the institution~  * International normalized ratio (INR) within normal limits for the institution (unless due to oral anticoagulation)~8. Performance status (ECOG) ≤ 1~9. Life expectancy ≥ 3 months.~10. Left ventricular ejection fraction (LVEF) within normal limits for the institution (LVEF of at least 50%).~11. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include complete abstinence, Intrauterine device, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository).~Exclusion Criteria:~1. Prior therapy with PM00104~2. Pregnant or lactating women.~3. Less than 4 weeks from radiation therapy (8 weeks in case of extensive prior radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy (6 weeks in case of nitrosourea, mitomycin C).~4. Prior high dose chemotherapy that needed bone marrow transplant support.~5. Subjects with untreated or uncontrolled brain or meningeal metastases.~6. Other relevant diseases or adverse clinical conditions:~   * Increased cardiac risk as defined by:~     * History or presence of unstable angina.~    * History or presence of myocardial infarction.~    * Congestive heart failure.~    * Symptomatic arrhythmia or any arrhythmia requiring ongoing treatment.~    * Abnormal ECG (i.e., patients with the following are excluded: QT prolongation-corrected QT interval \> 480 msec-, signs of cardiac enlargement or hypertrophy, bundle branch block, partial bundle branch blocks, signs of ischemia or necrosis, Wolff-Parkinson-White patterns).~    * History or presence of valvular heart disease.~    * Uncontrolled arterial hypertension despite optimal medical therapy.~    * Previous mediastinal radiotherapy.~    * Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m2~  * History of significant neurological or psychiatric disorders.~  * Active infection.~  * Significant non-neoplastic liver disease (e.g., cirrhosis, chronic active hepatitis).~  * Significant non-neoplastic renal disease.~  * Immunocompromised subjects, including subjects known to be infected by human immunodeficiency virus (HIV).~  * Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) requiring relevant changes in medication within the last month or hospital admission within the last 3 months.~  * Any other major illness that, in the investigator's judgment, could substantially increase the risk associated with the subject's participation in this study.~7. Limitation of the subject's ability to comply with the treatment or to follow-up at a participating center. Subjects registered on this trial must be treated and followed at a participating center.~8. Treatment with any investigational product in the 30 days period prior to the first infusion.~9. Known hypersensitivity to any of the components of the drug product, including sucrose or potassium phosphate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zalypsis (PM00104) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).